Ligand Pharmaceuticals, Inc.
http://www.ligand.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ligand Pharmaceuticals, Inc.
FDA Leaves Door Open For Further Discussions With Agenus Over BOT/BAL
The biotech company surprised observers when it announced the agency advised against filing for accelerated approval of the CTLA-4/PD-1 combination.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout
The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and markets in all of them except mainland China.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Ab Initio Biotherapeutics
- Crystal Bioscience, Inc.
- CyDex Pharmaceuticals, Inc.
- Icagen Pharmaceuticals, Inc.
- Metabasis Therapeutics, Inc.
- Neurogen Corporation
- Pharmacopeia, Inc.
- Pfenex Inc.
- Verrow Pharmaceuticals, Inc.
- Vernalis Group plc
- Cita NeuroPharmaceuticals
- Taurus Biosciences LLC
- xCella Biosciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice